Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

114 results
Display

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy

Kim MJ, Kim E, Kang B, Choe YH

Purpose: We aimed to investigate clinical outcomes between top-down (TD) and conventional step-up (SU) therapies in pediatric patients with moderate to severe ulcerative colitis (UC). Materials and Methods: All patients underwent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab

Choi S, Choi BS, Choe BH, Kang B

Vedolizumab (VDZ) has been approved for the treatment of inflammatory bowel diseases (IBDs) in patients aged ≥18 years. We report a case of a pediatric patient with Crohn disease (CD)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease

Kim JY, Lee Y, Choe BH, Kang B

Background/Aims: Anti-drug antibodies (ADAs) can develop during treatment with anti-tumor necrosis factor (TNF) agents. We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis

Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK

Background/Aims: Infliximab (IFX) has proven effective as rescue therapy in steroid-refractory acute severe ulcerative colitis (ASUC), however, the long-term real-world data are scarce. Our study aimed to assess the long-term...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Refractory brainstem encephalitis mimicking progressive cerebral infarction: infliximab and methotrexate as a salvage immunotherapy

Ahn SH, Roh J, Woo KN, Kim HS, Park MG, Park KP, Baik SK, Shin JH

Background: Brainstem encephalitis is a rare, severe, and potentially life-threatening inflammation of the central nervous system, exhibiting various treatment responses and outcomes owing to multiple etiologies. Case Report: We describe...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH

Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no headto-head comparison of treatment efficacy and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan

Shimizu H, Arai K, Takeuchi I, Minowa K, Hosoi K, Sato M, Oka I, Kaburaki Y, Shimizu T

Purpose: The long-term efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC) have not been well-evaluated. Here, we reviewed the long-term durability and safety of IFX in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease

Jung YS, Han M, Park S, Cheon JH

Background/Aims: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We compared the key clinical outcomes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab

Jung HI, Kim HJ, Kim JM, Lee JY, Park KS, Cho KB, Lee YJ

Relapsing polychondritis (RP) is a rare, progressive immune-mediated systemic inflammatory disease of unknown etiology, characterized by recurrent inflammation of cartilaginous structures. Approximately 30% of RP cases are associated with other...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies

van Rheenen H, van Rheenen PF

PURPOSE: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
History and Future of Treatment for Acute Stage Kawasaki Disease

Ishii M, Ebato T, Kato H

Kawasaki disease is a form of vasculitis, mainly in small and medium arteries of unknown origin, occurring frequently in childhood. It is the leading form of childhood-onset acquired heart disease...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Toxic Epidermal Necrolysis complicating Infliximab therapy in Refractory Kawasaki disease

Kwak A, Kim SA, Choi HJ

Severe skin reactions complicating tumor necrosis factor-alpha (TNF-α) antagonist therapy were somewhat reported in adults. We report a case of 24-month-old boy with refractory Kawasaki disease who developed toxic epidermal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study

Han M, Jung YS, Cheon JH, Park S

PURPOSE: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with ulcerative colitis (UC) are extremely limited, especially in the Asian population. We compared clinically important...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis

Jun YK, Chun J, Kang EA, Lee HJ, Im JP, Kim JS

Anti-tumor necrosis factor (anti-TNF) is an effective biological agent for the treatment of moderate-to-severe active ulcerative colitis (UC) refractory to conventional therapy. On the other hand, anti-TNF therapy is strongly...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease

Choi SY, Kang B, Choe YH

BACKGROUND/AIMS: Infliximab (IFX) often loses its therapeutic effect in initial responders with inflammatory bowel disease (IBD) over time. Low serum IFX trough levels (TLs) are linked to poor clinical response...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia G, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu , Yang SK, Ouyang Q, Geary R, De Silva J, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW, on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis

The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease

Woo MH, Cho YH, Sohn MJ, Lee EJ, Kim JW, Moon JS, Ko JS, Kim HY

PURPOSE: Pediatric Crohn's disease (CD) is directly related to growth and has a high probability of requiring surgical intervention(s); therefore, more active treatment for CD is required for children. This...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Infliximab-Induced Lupus in Crohn's Disease

Choi SJ, Kim S, Kim HY, Lee Y, Hyun DG, Yang SK, Kim YG

Infliximab (IFX) is an anti-tumor necrosis factor (TNF) monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Rarely, anti-TNF-induced lupus (ATIL) may occur. ATIL differs from classical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of severe hidradenitis suppurativa with biologic therapy and wide excision

Lim SY, Cheong EC, Oon HH

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea

Hur G, Song MS, Sohn S, Lee HD, Kim GB, Cho HJ, Yoon KL, Joo CU, Hyun MC, Kim CH

BACKGROUND AND OBJECTIVES: We investigated the status of infliximab use in intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients and the incidence of coronary artery aneurysms (CAAs) according to treatment regimens. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr